 Alterity Therapeutics ASX: ATH, NASDAQ: ATHE Alterity or the Company is pleased to announce that it has received guidance from the US Food and Drug Administration FDA in relation to the development pathway for ATH434 previously PBT434, the companys lead compound for the treatment of Multiple System Atrophy MSA, a Parkinsonian disorder. 